AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.

Sanofi launched a new corporate signature last week summing up its mission in two words: “Empowering Life," along with a global digital campaign.

Salix Pharmaceuticals' research found that many people who might have IBS are undiagnosed, leading to a show about IBS-D on the Lifetime Channel.

GlaxoSmithKline has the official go-ahead for its next big launch, the $1 billion vaccine prospect Shingrix.

Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S.

Here’s a sentence Bristol-Myers Squibb should be used to by now: England’s cost watchdogs have decided not to back routine NHS coverage of Opdivo.

When the year began, the prospect of U.S. tax reform had pharma companies salivating for some M&A action. But so far, that hasn't happened.

AZ and Chi-Med scores early data for savolitinib combos in lung cancer, WuXi AppTec buys a U.S. CRO, FDA clears Sun's Dadra plant.

Merck & Co. plans to jettison three U.S. sales teams and 1,800 associated staffers while creating a new, 960-employee chronic care force.